Zhong Guo Zheng Quan Bao·2026-01-14 22:54Core Insights - The sixth batch of centralized procurement for high-value medical consumables in China has been successfully conducted, involving 12 types of medical consumables with 496 products from 227 companies bidding, and 440 products from 202 companies proposed for selection [1] - The procurement includes drug-coated balloons and urological intervention consumables, with a focus on ensuring a diverse supply and meeting clinical needs [2] Procurement Details - Drug-coated balloons, which help alleviate vascular stenosis, were included in this procurement, with 42 products from 32 companies proposed for selection, ensuring high clinical compatibility while reducing costs for patients [2] - Urological intervention consumables, previously a "blank area" in procurement, saw 454 products from 195 companies bidding, with 398 products from 170 companies proposed for selection, addressing complex clinical needs [2] Selection Rules Optimization - The procurement process emphasizes principles such as maintaining clinical stability, ensuring quality, and preventing price undercutting, with a focus on grouping competition based on demand and supply capabilities [2] - A new rule was introduced to prevent extreme price competition, setting a price control benchmark at 65% of the average price when the lowest bid is excessively low, which was triggered in 8 out of 20 competitive groups [3] Market Impact - Leading companies are expected to gain more market share due to their successful bids in this procurement, with notable listed companies like Bluestar Medical and Lepu Medical participating [4] - The procurement is anticipated to standardize the purchasing and usage of medical consumables, thereby improving the industry ecosystem [4]